Industry Briefs: November 26, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: November 26, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Algeta and Ablynx have formed a research collaboration to evaluate the potential of novel alpha-pharmaceuticals comprising thorium-227 conjugated to tumor-targeting Nanobodies, a proprietary group of antibody-derived proteins. Read More

Cleveland BioLabs and Panacela Labs have announced an award of a contract valued at 146 million rubles ($4.6 million), with the Ministry of Industry and Trade of the Russian Federation for the development of Xenomycins, a family of compounds in development as anti-infective agents. Read More

Impax Laboratories will collaborate with Perrigo Company on the development, manufacturing, and commercialization of an extended topical generic-drug product. Read More

Unigene Laboratories and Tarix Pharmaceuticals have entered into a definitive licensing agreement to develop an oral formulation of TXA127, Tarix’s lead peptide drug candidate Read More

People News

Cambridge Major Laboratories has appointed Prasad Raje as vice-president of science and technology. Read More

Dr. Reddy’s Laboratories has appointed Umang Vohra as executive vice-president and head of the company’s North America generic-drug business, effective January 2013, and Saumen Chakraborty as chief financial officer, effective Jan. 2, 2013. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here